Blog

Boston-based Iora Health, the care team-oriented Medicare Advantage primary care provider, this month secured $100 million in funding to support its growth and technology platform.

Rushika Fernandopulle, MD, co-founder and CEO of Iora Health, spoke with HealthLeaders Media about the provider’s plans for expansion, and the care model that he believes can transform healthcare delivery.

MADISON, Wis. — The Wisconsin Statewide Health Information Network (WISHIN), Wisconsin’s designated entity for Health Information Exchange (HIE), is pleased to announce an innovative partnership with PatientPing, the nation’s leading care-coordination platform, to improve care coordination across hundreds of hospitals, clinics, post-acute care facilities, ACOs, health plans and other community health care organizations throughout Wisconsin.

Through this partnership, participating payers and providers will benefit from access to PatientPing’s real-time patient information– “Pings” and “Stories” –to better coordinate patient care. These notifications, from 1,500 sites of care in WISHIN’s statewide network, plus thousands more in PatientPing’s national network, offer payers and providers increased visibility into patient encounters outside their virtual four walls, and even across state lines. This advancement of care-coordination technology is especially valuable as providers become increasingly responsible for patient outcomes and as the federal government continues to push for increased interoperability across the care continuum.

Read More

Xconomy Boston — A global proliferation of subpar and fake prescription drugs is driving more investment into businesses combating the problem with new software-based systems for tracking the supply chain of pharmaceuticals.

TraceLink is one of those companies on the rise, and the North Reading, MA-based firm recently raised $60 million in a new venture capital round, according to a document filed with the SEC. That brings TraceLink’s total equity funding to at least $137.2 million, per SEC filings. Its investors include Goldman Sachs, FirstMark Capital, Volition Capital, and F-Prime Capital. TraceLink officials couldn’t be immediately reached for comment Monday morning.

TraceLink sells cloud-based software that enables companies in the pharmaceutical industry to perform various tasks around authenticating and tracking the drugs they work with. That includes meeting regulatory compliance standards, storing what can be a massive amount of data created by tracking individual packages of drugs, and interacting with other companies that use TraceLink (such as manufacturers coordinating with distributors).

As Xconomy has reported, the nine-year-old company aims to not only let customers track large amounts of data, but its software is also meant to let them exchange data on the platform, almost like a social network, co-founder and CEO Shabbir Dahod said in a 2015 interview.

Read More

NORTH READING, Mass. — TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced that it has developed a streamlined program for its more than 190 customers to rapidly complete conformance testing and successfully receive European Medicines Verification Organization (EMVO) approval to submit data to the EU Hub – a complex and lengthy process that requires each individual company to complete EMVO registration and provide a full set of test cases to be executed for conformance with the EU Hub.
In just one month, 34 companies have completed their conformance testing with TraceLink’s conformance test kit. Of these, 11 companies have received EMVO approval to submit data to the EU Hub and 14 companies are awaiting review from the EMVO. In order to achieve final approval, all pharmaceutical companies must now submit a series of transactions to be reviewed by the EMVO, a process that can now take several weeks due to the surge of companies seeking to connect to the EU Hub before the EU Falsified Medicines Directive (FMD) deadline in February 2019. Once the transactions are approved by the EMVO, a pharmaceutical company will receive access to the certificates required for production and data submission to the EU Hub.

Read More

Nationwide partnership solves for major issue in the industry by making it easy for consumers online to be transported to recommended care as soon as they realize something is wrong

BOSTON–(BUSINESS WIRE)–Circulation Health (www.circulation.com), a ride-ordering exchange that coordinates medical transportation logistics using Lyft and other transportation partners, today announced that it has entered into a nationwide partnership with Buoy Health (www.buoyhealth.com), to help millions of patients online receive the care they need when they need it the most. The partnership – which will roll out before the end of 2018 – will introduce Buoy’s patients to an even further streamlined, end-to-end healthcare experience by making it easy for them, post assessment, to book reliable on-demand transportation, powered by Circulation, to recommended care.

“Ultimately, it comes down to providing a better experience to individuals who need timely access to care,” said Robin Heffernan, CEO & Co-Founder of Circulation. “And since every patient journey starts with a ride, it makes so much sense to give Buoy users easy access to convenient, reliable transportation to their local pharmacies, primary care clinics, or urgent care centers.”

Read more

Combination of analytics, research, and performance improvement expertise to support evidence-based medical device and drug selection, utilization

CHICAGO–(BUSINESS WIRE)–Navigant (NYSE: NCI) and Lumere today announced a collaboration to help healthcare providers implement evidence-based, technology-enabled consulting solutions aimed at reducing clinical and financial variation. The goal of the collaboration is to assist hospitals and health systems with reducing unnecessary utilization of drugs and medical devices in such areas as orthopedic, spine, cardiac, and surgical services.

Research suggests up to a quarter of overall healthcare expenditures are wasteful and not associated with improved quality. A proven way to reduce waste is to target unnecessary variation in clinical processes. However, providers often lack the resources to analyze major clinical cost factors necessary to drive action.

Read more